Bayer’s asundexian cuts stroke risk 26% in phase III win

Thermo FisherTMO Thermo Fisher Scientific Inc falls 2.95 percent post Q4 2025 earnings despite narrow EPS beat and 3.9 percent year-over-year revenue growth. - Investment Community Signals - UBND thành phố Hải Phòng

FierceBiotechLilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors

Thermo FisherThermo Fisher (TMO) Q4 2024 Earnings Transcript - AOL.com

WatersWAT (Waters Corporation) rises 1.06 percent after Q4 2025 results, as 7 percent revenue growth offsets minor EPS miss. - Earnings Risk - Cổng thông tin điện tử Tỉnh Sơn La

FierceBiotechMcKesson swaps minority stake in surgical unit to Apollo Funds for $1.25B

FierceBiotechAcuityMD raises $80M to help bolster AI in the medtech industry

FierceBiotechAACR: NCI leader Letai battles ‘misinformation’ to assure anxious researchers that ‘funding is strong’

FierceBiotechMerck goes with Google for AI push, striking enterprise partnership worth up to $1B

BioWorldAppointments and advancements for April 22, 2026

BioWorldFinancings for April 22, 2026

BioWorldIn the clinic for April 22, 2026

BioWorldOther news to note for April 22, 2026